Related Experiment Video
Updated: Mar 29, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
Lisette B W Schröder1, Kerrie L McDonald2
1Erasmus Medical Center, Erasmus University Rotterdam , Rotterdam , Netherlands.
Abstract:
Glioblastoma is aggressive, highly infiltrating, and the most frequent malignant form of brain cancer. With a median survival time of only 14.6 months, when treated with the standard of care, it is essential to find new therapeutic options. A specific CDK4/6 inhibitor, PD0332991, obtained accelerated approval from the Food and Drug Administration for the treatment of patients with advanced estrogen receptor-positive and HER2-negative breast cancer. Common alterations in the cyclin D1-cyclin-dependent kinase 4/6-retinoblastoma 1 pathway in glioblastoma make PD0332991 also an interesting drug for the treatment of glioblastoma. Promising results in in vitro studies, where patient derived glioblastoma cell lines showed sensitivity to PD0332991, gave motive to start in vivo studies. Outcomes of these studies have been contrasting in terms of PD0332991 efficacy within the brain: more research is necessary to conclude whether CDK4/6 inhibitor can be beneficial in the treatment of glioblastoma.
Insights
Glioblastoma treatment shows promise with CDK4/6 inhibitors like PD0332991, but in vivo study results are mixed. Further research is needed to confirm its efficacy for brain cancer.
Area of Science:
- Neuro-oncology
- Molecular targeted therapy
- Cancer cell biology
Background:
- Glioblastoma is an aggressive brain cancer with poor prognosis.
- Current standard treatments offer limited survival benefits.
- The cyclin D1-CDK4/6-RB pathway is frequently altered in glioblastoma.
Purpose of the Study:
- To investigate the potential of the CDK4/6 inhibitor PD0332991 for glioblastoma treatment.
- To evaluate the efficacy of PD0332991 based on in vitro and in vivo study outcomes.
Main Methods:
- In vitro studies using patient-derived glioblastoma cell lines.
- In vivo studies to assess PD0332991 efficacy in a brain cancer model.
Main Results:
- Patient-derived glioblastoma cells demonstrated sensitivity to PD0332991 in vitro.
- In vivo study outcomes regarding PD0332991 efficacy within the brain were contrasting.
Conclusions:
- PD0332991 shows potential as a glioblastoma therapeutic agent based on in vitro data.
- Further investigation is required to determine the clinical benefit of CDK4/6 inhibitors in glioblastoma treatment.
